{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-000128","form_type":"8-K","ticker":"HRMY","cik":"0001802665","company_name":"Harmony Biosciences Holdings, Inc.","filed_at":"2024-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.588859+00:00","generated_at":"2026-06-07T02:29:47.151465+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Harmony Biosciences reports Q4 net product revenue ~$168M, FY2023 ~$582M; 2024 guidance $700-720M","bullets":["Preliminary Q4 net product revenue ~$168M, up ~31% YoY; FY2023 ~$582M, up ~33% YoY.","Average WAKIX patients ~6,150 in Q4 2023; 2024 target ~7,000 patients.","2024 net product revenue guidance of $700M to $720M.","Repurchased ~1.8M shares for $50M in Q4 2023; $150M remaining authorization."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-000128","json":"https://secwatch.observer/filing/0001558370-24-000128.json","markdown":"https://secwatch.observer/filing/0001558370-24-000128.md","text":"https://secwatch.observer/filing/0001558370-24-000128.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1802665/000155837024000128/0001558370-24-000128-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1802665/000155837024000128/hrmy-20240108x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T02:29:47.151465+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ad752d8de2d7f9dc1c87bf389c3fc46a6a36a28c","claim":"Harmony Biosciences Holdings, Inc. reported 2024 results: revenue $700 million to $720 million. Guidance initiated.","evidence_excerpt":"Expect full year 2024 net product revenue of $700 million to $720 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1802665/000155837024000128/0001558370-24-000128-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"2024"},{"label":"Revenue","value":"$700 million to $720 million"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"ba69550b255195281ec2518b083e5cd4f2fefec4","claim":"Harmony Biosciences Holdings, Inc. reported the fourth quarter ended December 31, 2023 results: revenue approximately $168 million. Guidance raised.","evidence_excerpt":"Preliminary, unaudited net product revenue for the quarter ended December 31, 2023, was approximately $168 million, compared to $128.3 million for the same period in 2022, representing ~31% growth","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1802665/000155837024000128/0001558370-24-000128-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter ended December 31, 2023"},{"label":"Revenue","value":"approximately $168 million"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"},{"claim_id":"d3b1c977c0f8f81e553d846bbe41d52980f39050","claim":"Harmony Biosciences Holdings, Inc. reported the full year ended December 31, 2023 results: revenue approximately $582 million. Guidance raised.","evidence_excerpt":"Preliminary, unaudited net product revenue for the full year ended December 31, 2023, was approximately $582 million, compared to $437.9 million for the same period in 2022, representing ~33% growth","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1802665/000155837024000128/0001558370-24-000128-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year ended December 31, 2023"},{"label":"Revenue","value":"approximately $582 million"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}